Skip to main content
Equibles

Sumant Kolkarni

Analyst

Canaccord

Equibles does not estimate personal net worth.

About Sumant Kolkarni

Sumant Kolkarni is recorded as Analyst at Canaccord. Sumant Kolkarni has spoken on 2 earnings calls across 2 companies, most recently for Zevra Therapeutics, Inc. on May 6, 2026. Those appearances were for Zevra Therapeutics, Inc. (ZVRA) and Neurocrine Biosciences Inc (NBIX). The companies whose calls Sumant Kolkarni spoke on are classified in the Healthcare sector.

Sumant Kolkarni on recent calls

“On Celeptrolol, we know you plan to meet with the FDA again in the second half of this year, but what are some of the specific options that you might have on the table in terms of your ability to move faster to bring this product to wedge patients.”
Analyst — Canaccord, Zevra Therapeutics, Inc. Q1 FY2026 Earnings Call ·
“It looks like you sold your UK and European rare commercial business recently. What does this mean for your plans to develop Crenesofront in UK and the rest of Europe?”
Analyst — Canaccord, Neurocrine Biosciences Inc Q4 FY2025 Earnings Call ·

Affiliation history

  • Canaccord

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity